PEX14

Peroxisomal membrane protein PEX14 · O75381 · PEX14 on Sugi Atlas →

313 patent compounds predicted against PEX14, 195 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL17554524 SCHEMBL17554524 1.00 20/20
SCHEMBL17576656 SCHEMBL17576656 1.00 20/20
SCHEMBL17576677 SCHEMBL17576677 1.00 20/20
SCHEMBL17576678 SCHEMBL17576678 1.00 20/20
SCHEMBL17576846 SCHEMBL17576846 1.00 20/20
SCHEMBL17576889 SCHEMBL17576889 1.00 20/20
SCHEMBL17576890 SCHEMBL17576890 1.00 20/20
SCHEMBL19294059 SCHEMBL19294059 1.00 20/20
SCHEMBL19294060 SCHEMBL19294060 1.00 20/20
SCHEMBL19294063 SCHEMBL19294063 1.00 20/20
SCHEMBL19294064 SCHEMBL19294064 1.00 20/20
SCHEMBL19294065 SCHEMBL19294065 1.00 20/20
SCHEMBL19294066 SCHEMBL19294066 1.00 20/20
SCHEMBL19294074 SCHEMBL19294074 1.00 20/20
SCHEMBL19294075 SCHEMBL19294075 1.00 20/20
SCHEMBL19294081 SCHEMBL19294081 1.00 20/20
SCHEMBL19294090 SCHEMBL19294090 1.00 20/20
SCHEMBL30933543 SCHEMBL30933543 1.00 20/20
SCHEMBL19294116 SCHEMBL19294116 0.91 20/20
SCHEMBL17576849 SCHEMBL17576849 0.89 20/20

Clinical trials — most relevant to PEX14 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Compare the Impact of Xuezhikang and Atorvastatin on Glucose Metabolism in Dyslipidemia Patients With Prediabetes PHASE4COMPLETED
Pioglitazone Study of Triglyceride Changes in Subjects With Type 2 Diabetes After Conversion From Rosiglitazone. PHASE4COMPLETED
Betaine and Peroxisome Biogenesis Disorders PHASE3COMPLETED
TMC114-C209: A Study of Safety of TMC114 With Low Dose Ritonavir (RTV) and Other Antiretrovirals in Experienced HIV-1 Infected Patients With Limited or no Treatment Options PHASE3COMPLETED
A Study of Bezafibrate in Mitochondrial Myopathy PHASE2COMPLETED
Targeting Endoplasmic Reticulum Stress in Human Hypertension PHASE1/PHASE2RECRUITING
Cholic Acid for Hepatic Steatosis in Lipodystrophy PHASE2COMPLETED
A Supervised Nutritional Program in Pregnancies and NF-κB Expression in Placenta PHASE1COMPLETED
Vitreous Proteomics of Patients Suffering From Pseudoexfoliation Syndrome nanACTIVE_NOT_RECRUITING
Plasma Levels of Matrix Metalloproteinases (MMPs) and Degree of DNA Fragmentation in Pseudoexfoliation (PEX) Glaucoma nanCOMPLETED
Evaluation of a New Strategy for the Diagnosis of Peroxisomal Diseases nanCOMPLETED
Evolution of Visual Impairment During Pseudoxanthoma Elasticum nanCOMPLETED
Comparison of Phoenixin-14 Levels in Term Babies nanCOMPLETED
The Effect of Laparoscopic Sleeve Gastrectomy on Blood Phoenixin-14 Levels nanCOMPLETED
the Role of plin5 in the Development of Nonalcoholic Fatty Liver Disease. nanUNKNOWN
Investigating the Genetic Basis of Pseudoexfoliation Syndrome, Angle-closure Glaucoma and Primary Open-angle Glaucoma nanRECRUITING
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
Multi-Dimensional Genomic Dissection of Ring Chromosome 14 Syndrome nanACTIVE_NOT_RECRUITING
Macrophages, GM-CSF and MARS Proteinosis nanCOMPLETED
Longitudinal Prospective Natural History Study of Retinopathy in Zellweger Spectrum Disorder nanRECRUITING
Screening for Hepatitis Virus B Protein X (HBx) in Colitis-associated Cancer (CAC) nanNOT_YET_RECRUITING
Classification, Functional Stratification and Biomarkers in Ciliopathy (CILLICORIRCM) nanCOMPLETED
Neutrophils as Prognostic Factors in Granulomatosis With Polyangiitis (Formerly Named Wegener's Granulomatosis) nanCOMPLETED
Gastrostomy-Biliary Diversion: Innovative Management for Bile Canalicular Transport Disorders nanUNKNOWN
Hydroxychloroquin (HCQ) in chILD of Genetic Defect nanCOMPLETED
Whole Exome and Whole Genome Sequencing for Genotyping of Inherited and Congenital Eye Conditions nanRECRUITING
Targeting Oxidative Stress to Prevent Vascular and Skeletal Muscle Dysfunction During Disuse nanACTIVE_NOT_RECRUITING
Serum Betatrophin Levels and Its Influencing Factors in Patients With Hyperthyroidism nanUNKNOWN
Clinical and Genetic Analysis in Congenital Hypothyroidism Due to Thyroid Dysgenesis. nanCOMPLETED
Familial Partial Lipodystrophy Study nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a PEX14 binder may also engage these)

ProteinNameSimilarity
Q9R0A0 1.000 Q9R0A0 →
Q9Z2Z3 1.000 Q9Z2Z3 →
Q642G4 1.000 Q642G4 →
Q8K0V4 0.993 Q8K0V4 →
Q9HG09 0.992 Q9HG09 →
A0A0R4IZ84 0.992 A0A0R4IZ84 →
Q6NZJ6 0.992 Q6NZJ6 →
Q8BG95 0.992 Q8BG95 →
Q8IZ21 0.992 Q8IZ21 →
O60237 0.991 O60237 →
P78723 0.991 P78723 →
Q9DB00 0.991 Q9DB00 →
A5DLJ8 0.991 A5DLJ8 →
Q9D3S3 0.991 Q9D3S3 →
Q80Y56 0.991 Q80Y56 →
Q5XG48 0.991 Q5XG48 →
Q5RAK6 0.991 Q5RAK6 →
Q8IYB4 0.990 Q8IYB4 →
Q9D8L5 0.990 Q9D8L5 →
Q8BHX3 0.990 Q8BHX3 →
Q9ERE6 0.990 Q9ERE6 →
Q8WZL6 0.990 Q8WZL6 →
O35711 0.990 O35711 →
P84903 0.990 P84903 →
A7YDW0 0.990 A7YDW0 →
A5WV69 0.990 A5WV69 →
B5X601 0.989 B5X601 →
Q6AY97 0.989 Q6AY97 →
Q7SXL7 0.989 Q7SXL7 →
Q6DD45 0.989 Q6DD45 →